NCT02446652 2025-05-29
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer
National Institute of Cancerología
Phase 3 Withdrawn
Clinical Trials
9 trialsNCT00996060 2016-01-18
Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00575640 2015-03-04
Hydralazine as a Demethylating Agent in Rectal Cancer
University of Arkansas
Phase 1/2 Withdrawn
NCT00575978 2015-03-04
Hydralazine as Demethylating Agent in Breast Cancer
University of Arkansas
Phase 1/2 Withdrawn
NCT00532818 2009-03-30
Hydralazine Valproate for Cervical Cancer
National Institute of Cancerología
Phase 3 Unknown
NCT00533299 2007-09-21
Hydralazine Valproate for Ovarian Cancer
National Institute of Cancerología
Phase 3 Unknown
NCT00404326 2006-11-28
Hydralazine and Valproate Plus Cisplatin Chemoradiation in Cervical Cancer
National Institute of Cancerología
Phase 2 Completed
NCT00404508 2006-11-28
A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
National Institute of Cancerología
Phase 2 Completed
NCT00395655 2006-11-03
Hydralazine and Valproate Added to Chemotherapy for Breast Cancer
National Institute of Cancerología
Phase 2 Terminated